Revision History

The 2026 ACC/AHA dyslipidemia guidelines mark the most significant overhaul of U.S. cholesterol management in over a decade, reinstating specific LDL targets abandoned since 2013, lowering the age for risk assessment to 30, and recommending universal lipoprotein(a) screening. While supporters say the changes could prevent millions of heart attacks and strokes, critics point to industry ties among committee members and warn that nearly half of the guideline's top-tier recommendations lack randomized trial evidence.